Background
The percutaneous treatment of patients with obstructive atherosclerotic disease in coronary saphenous vein bypass grafts (SVG) remains a challenge in interventional cardiology. Patients undergoing SVG intervention are often older, and suffer significant comorbidities. Moreover, SVGs usually present a degenerated pattern of atherosclerosis, with complex, friable, thrombotic-prone lesions. SVG interventions carry a higher risk of acute complications, mainly distal embolisation, and poorer long-term outcomes, mainly restenosis, than do native coronary vessel interventions 1, 2 . The predictors of one-month major cardiac events after SVG intervention have been explored recently 3 . The degree of SVG degeneration assessed by the SVG degeneration score, the estimated plaque volume, angiographic evidence of thrombus, and increasing patient age are the correlates associated with the 30-day composite outcome of death, myocardial infarction (MI) and target lesion revascularisation (TLR). Thus, an important reason for poorer outcomes of percutaneous coronary interventions (PCI) in SVGs is the embolisation of atherothrombotic debris into the native coronary circulation, often resulting in periprocedural MI or reduced antegrade flow ("no-reflow"). Strategies for addressing this distal embolisation problem include both proximal and distal protection devices, as well as adjunctive pharmacology and stenting approaches. Embolic protection devices have demonstrated value in decreasing the risk of embolisation and post-procedural myocardial enzyme elevation after SVG intervention. While stenting has definitely been proved to be superior to balloon-only angioplasty for the treatment of SVG lesions, the choice of the type of stent (bare metal stent versus drugeluting stent) is still a matter of debate. Drug-eluting stents appear promising for the successful sealing of SVG disease; however, available long-term safety and effectiveness data are conflicting and give reason for caution.
Natural history of SVG disease
The SVG disease process involves three interlinked pathophysiological phenomena which lead to progressive degeneration: thrombosis, intimal hyperplasia, and atherosclerosis.
THROMBOSIS
About 10% of SVGs occlude, with or without symptoms, within the first month after coronary artery bypass graft (CABG) surgery. This early phenomenon seems to be related to severe endothelial cell loss and medial damage during harvesting. In addition, this prothrombotic stage of SVG may be amplified by technical factors which reduce graft flow, such as intact venous valves, anastomosis stricture, and graft anastomosis proximal to diseased segments. In summary, PCI is usually preferred over repeat CABG for early recurrent symptoms after CABG (<3 years). For late graft failure, because of the initial higher mortality of redo CABG and the comparable long-term mortality, PCI is the preferred revascularisation strategy in patients with patent left IMA and amenable anatomy. However, most symptomatic post-CABG patients present with extensive native and graft disease where the revascularisation strategy must be based on careful risk/benefit assessment of the procedure and the local experience. The most important factors involved in the choice of repeat CABG are more extensive SVG/native disease, lower left ventricular ejection fraction, longer interval from first CABG, more total occlusion of native arteries, and the absence of patent IMA graft. The IMA is the conduit of choice for revascularisation during redo CABG.
Difficulties and methods
When dealing with a percutaneous intervention for an SVG lesion, pharmacological pre-treatment of the patient is important. Dual antiplatelet therapy (with a thienopyridine given upfront) and statins are mandatory, unless clearly contraindicated. Periprocedural glycoprotein IIb/IIIa inhibitors do not seem to be effective in SVG interventions 5 . However, in cases of acute myocardial infarction due to acute graft closure and the possibly high burden of acute, non-organised thrombus, we still suggest using these drugs.
ACCESS SITE AND GUIDING CATHETER CHOICE
For SVG there is no specific reason to choose either the radial or the femoral approach besides the known risks/benefits of each access site, the choice of the patient and the experience of the operator. In our experience, when using radial access, a left radial approach is more suitable for SVG, originating from the left anterior wall of the aorta and directed to the left coronary artery. For these SVG, mainly if their aortic anastomosis is high in the ascending aorta, the right radial approach offers poor support and the choice of the guiding catheter remains complicated and poorly predictable. On the other hand, for SVG from the right or posterior wall of the aorta (usually directed to the right coronary artery or sometimes to the circumflex territory) right and left radial approaches are equivalent. Choosing the correct guiding catheter is a very important step. In our experience, for SVG to the right coronary artery, originating most of the time from the right anterior surface of the aorta, the multipurpose catheter has the best alignment and support when performing the procedure via either the femoral or the radial artery. Engagement of the catheter can be performed in the left anterior oblique view. For vein grafts originating from the left anterior surface (usually to the left anterior descending/diagonal or marginal/circumflex arteries), we prefer Judkins right or left coronary bypass catheters (the best fitting catheter can be tested during the diagnostic angiography) in case of femoral access. If additional support is needed, Amplatz left catheters can be used. Engagement is feasible in the right anterior oblique view. When approaching these bypasses via the radial approach, as previously mentioned, we recommend choosing the left radial artery. Guiding catheters of choice can be extra back-upshaped or Amplatz left catheters. Sometimes vein grafts to the circumflex originate from the posterior surface of the aorta. In this case, Amplatz left or multipurpose guiding catheters are preferred, and engagement is performed in the right anterior oblique view.
EMBOLIC PROTECTION
The "mechanical" protection of the vasculature distal to the treated SVG lesion is the only strategy, up to now, soundly proven to reduce distal embolisation and periprocedural MI. Indeed PCI of SVG should always be performed under embolic protection device. So far, three types of device have been developed with this scope.
The first to be tested in SVG was a distal occlusion device (Figure 1-Figure 3) . Its mechanism is as follows. A compliant balloon, directly present in the distal tip of a guidewire specifically made with this feature, is positioned distal to the lesion before the PCI and is inflated at low pressure during the procedure (using a dedicated device that introduces water through the special wire itself), creating a temporary occlusion of the vessel. Suction of the stagnant blood/debris is done just after the PCI using an aspiration catheter inserted through the guiding catheter over the special wire, and the balloon is then deflated. In the randomised Saphenous Vein Graft Angioplasty Free of Emboli Randomized (SAFER) trial, this device was shown to reduce significantly the incidence of major adverse clinical events at 30 days compared to the simple implantation of stent without distal protection. This benefit was largely driven by a reduction in the rate of periprocedural MI 6 . A second distal occlusion device has also been tested effectively and is available on the market 7 .
Distal filters have the same rationale but a different mechanism of action from the distal occlusion device (Figure 4-Figure 6) . A distal filter is a porous filter, which is placed distally to the lesion before the PCI in order to collect embolic material and retrieve it after the procedure. The value of the first commercialised filter has been proven in the Filterwire Randomized Evaluation (FIRE) trial, a large randomised study, in which the filter was shown to be noninferior to the previously described "occlusion and aspiration" system 8 . Several filters have recently been released onto the market, some with proven non-inferiority as compared with the approved protection devices 9 , some without clear evidence of benefit 10, 11 . The last embolic protection device is the proximal protection device (Figure 7-Figure 9 ). This is a catheter with a specific protection balloon on its distal tip, guided inside a standard guiding catheter up to the ostium of the vein graft proximal to the lesion site (similar to a mother-and-child technique). At this level the balloon is inflated temporarily, occluding blood flow and creating a column of stagnant blood, so that the debris dislodged during the PCI (which is performed through the device itself) can then be aspirated from the vessel through the same catheter. The Proximal Protection During Saphenous Vein Graft Intervention Using the Proxis Embolic Protection System (PROXIMAL) trial compared this proximal protection device with currently available distal protection devices (either occlusion-based or filters) showing non-inferiority of the study device 12 . Despite this large body of evidence and the guidelines, embolic protection devices remain underutilised in daily practice. The elevated cost of these devices seems to be a major explanation for their low utilisation. Moreover, the fact that there is a learning curve can also play a role in the speed of their adoption in clinical practice. We recommend that operators select a couple of embolic protection devices which they can utilise regularly to build up experience with and confidence in their use. Protection devices can eventually be avoided in cases of very focal lesions in small (<3.5 mm) grafts. In this case, a soft-tip coronary guidewire and direct stenting without predilatation and post-dilatation should be the recommended strategy. Choosing the type of protection device depends mainly on the location of the lesion, on the tolerance of the patient to prolonged ischaemia and on the operator's personal experience with the device. In cases of proximal or ostial lesions, distal protection devices should be recommended. In cases of distal lesions, a proximal protection device fits better. The theoretical background for these choices relies on the fact that every protection device needs a vein graft disease-free landing zone of around 3-5 cm. In case of lesions in the mid body of the graft, any type of protection device is usable. In this instance, an important consideration for the choice of the device is the tolerance of the patient to ischaemia. Indeed, proximal protection devices and distal occlusion devices require a prolonged time of ischaemia (in our experience, usually two to four minutes) due to the temporary occlusion of the SVG by means of the inflated low-compliance balloon. On the contrary, filters allow performance of the procedure without interruption of blood flow and should be preferred in more unstable patients with poorer left ventricular function, or in SVG with a very large area of myocardium downstream. When using a protection device, the careful positioning of the device itself (the low-compliance balloon or the filter) in an angiographically disease-free zone is the first step. If possible, the proximal protection device can be tracked in the SVG to approximate the lesion, thus improving the support of the catheter itself for the procedure. In case of proximal or distal occlusion protection devices, the effectiveness of adequate and complete vessel occlusion should be assured. This means that a column of stagnant blood (checked with contrast) should be evident once the device is in place and inflated. If a filter is used, we recommend securing appropriate deployment of the filter (good apposition to the vessel wall) in two orthogonal views. An additional tip, in case of filter use and in case of a poorly supportive guiding catheter, is to place an additional conventional coronary guidewire in the SVG before placing the filter. This helps to stabilise the system and improves trackability of subsequent devices. Once the protection device is in place, we always recommend direct stenting and, in case the stent remains significantly underdeployed, high-pressure post-dilatation must be done with a protection device in place.
Figure 9. Proximal occlusion device mechanism of action: A) severe stenosis in the mid portion of a saphenous vein graft to the right coronary artery. B) proximal protection device in place with balloon inflated (arrow: distal tip of the device, where the non-compliant balloon is; arrowhead: distal tip of the guiding catheter) and stent in place and inflated (white dotted line). Note the stagnant column of contrast before and after the inflated stent. C) Final result.
Once the stenting procedure is finished, care should be given to the collection of debris from the protection device and to retrieval of the device itself. With proximal device placement, direct aspiration of at least 5 cc of blood from the device should be performed before releasing the occlusion. In case of distal occlusion device use, the specific manual aspiration device should be used, and two syringes of 20 cc of blood should be aspirated. If a filter is used, careful, complete closure of the filter with a dedicated retrieval catheter is necessary before retrieval of the filter. We recommend performing the complete procedure under fluoroscopy. Final angiographic control of the stenting procedure without a device in place is mandatory in at least two orthogonal views.
Although definitive data coming from randomised trials are lacking, "pharmacologic" protection targeted at improving microvascular flow dynamics with intra-graft administration of vasodilators (such as adenosine, nitroprusside, verapamil or nicardipine) is considered another possible prophylactic treatment for the prevention of no-reflow. Currently, due to the lack of clear evidence about these agents, we do not perform routine prophylactic administration of these agents before SVG PCI, but only as "bail-out" in case of proven no-reflow just after PCI.
Stent choice
While stenting has been definitely proven superior to balloon-only angioplasty in SVG intervention 13 , the specific type of stent (bare metal or drug-eluting) is still a matter of debate. In almost all pivotal randomised trials, SVG lesions were excluded. The mechanisms of the in-stent restenotic process in SVG are different when compared to native arteries. Furthermore, the problem of higher local prothrombotic conditions in SVG and the expected delay in endothelial healing after drug-eluting stent (DES) placement are claimed to be possible drawbacks of DES implantation in SVG, as they can potentially lead to a higher risk of stent thrombosis. Thus, clear and available data concerning the safety and the efficacy of these devices in SVG are needed before a routine application of DES in this lesion subset can be approved.
There are currently three randomised studies specifically performed in SVG: the single-centre double-blind "Reduction of Restenosis In Saphenous vein grafts with Cypher stent" (RRISC) trial, comparing in 75 patients sirolimus-eluting stents and the respective uncoated bare metal stents (BMS) 14 , the multicentre single-blind "Stenting of Saphenous Vein Grafts" (SOS) trial, comparing in 80 patients paclitaxel-eluting stents and the respective uncoated BMS 15 , and the multicentre "Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts" (ISAR CABG) trial comparing in 610 patients three different DES (sub-randomised to paclitaxel-eluting stents, permanentpolymer sirolimus-eluting stents, or biodegradable-polymer sirolimus-eluting stents) versus BMS 16 .
All these trials showed significant reduction of angiographic and clinical restenosis with DES compared with BMS at one-year follow-up. However, longer-term follow-up post hoc analyses of the RRISC and of the SOS trials showed conflicting clinical results. The SOS trial reported sustained benefit, with DES significantly reducing repeated revascularisation procedures without any significant difference in mortality 17 . The RRISC trial showed a notable increase in mortality with DES, also with attrition in revascularisation difference that disappeared at three-year follow-up 18 . The longterm results of the much larger ISAR CABG trial are eagerly awaited and will shed additional light on the topic.
At a lower level of evidence with respect to randomised trials, several registries have assessed the mid-term and long-term safety and effectiveness of DES in SVG 19 . Overall, while in all studies with follow-up <1 year the benefits of DES in terms of reduction of repeated revascularisation procedures seem evident, at longer term several studies have not shown significantly different revascularisation outcomes between DES and BMS, while a few studies have demonstrated only moderate advantages, clearly not comparable to the benefits shown in native coronary arteries. On the other hand, safety issues, such as those seen in the long-term follow-up of the RRISC trial, have never been confirmed. All these data underline the fact that DES can be considered effective and safe at short-term (one year) follow-up as consistently shown in several studies; however, longer-term follow-up of adequately performed studies is required to confirm that DES remain safe and effective also after one year. While awaiting these studies, our policy is to implant BMS as first choice for de novo SVG lesions and, in case of restenosis, which in any case has a different, less thrombus-prone physiopathological substrate than native vein graft disease, DES.
Concerning the implantation strategy, independently from the type of stent chosen, we almost always definitely recommend attempting direct stenting. In case of failure, we also suggest a low threshold for switching to balloon predilatation. Significantly undersized balloons should be favoured in case of predilatation in order to minimise plaque embolisation. In case of temporary occlusion of the SVG during direct stent placement and the impossibility of visualising with contrast the distal landing zone of the SVG, the clips present around the SVG can often be used as landmarks to improve accuracy in stent positioning and deployment, even without the help of contrast injections.
Other types of stent, so-called "covered" stents, have also been tested in SVG lesions. The rationale behind this type of stent was to prevent distal embolisation, as the stent itself, covered by a layer of polytetrafluoroethylene (PTFE), was supposed to trap friable plaque between the stent and the SVG wall. However, this theory proved false: PTFE-covered stents, in comparison to BMS, did not reduce the amount of distal embolisation and the rate of periprocedural MI, and showed no different, or even worse, clinical and angiographic restenosis 13 . Thus, the use of PTFE-covered stents in the treatment of SVG cannot be recommended. Nonetheless, new developments in the same concept have recently been undertaken. Preliminary experience using a newly developed system comprising a BMS platform with a polymeric net attached to its surface (supposedly able to entrap fibro-thrombotic material), appears to be a potentially interesting innovation to prevent distal embolisation and no-reflow in SVG PCI 20 . However, these data are preliminary and based on a small number of patients: once again, therefore, larger trials are definitely needed. In the meanwhile, this device should be used only in the setting of clinical studies.
Plaque sealing in SVG
Atherosclerosis in SVG is known to be markedly accelerated. The progression, in the short term, of SVG segments from previously non-significant lesions to new severe stenoses accounts for a considerable rate of SVG failure post PCI (Figure 10A-Figure10M) . Thus, the idea of treating SVG lesions before they become ischaemic ("plaque sealing") definitely remains appealing in SVG. This interesting concept has been tested in the small randomised "Moderate VEin Graft LEsion Stenting with the Taxus stent and Intravascular ultrasound" (VELETI) pilot trial with promising results 21 .
A 22% rate of progression from moderate non-ischaemic lesions to clinically severe stenoses was shown in only one year in the group treated conventionally, with medical therapy only. This indeed proves the rapidly evolving nature of SVG disease. In our routine, we tend to treat lesions in SVG in case they are angiographically >50% (and in case the PCI is technically feasible with an a priori low chance of having major complications), independently from the presence of proven ischaemia in the specific myocardial territory vascularised by the diseased SVG.
